In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
Tóm tắt
Abstract Patients with acute myeloid leukemia (AML) harboring internal tandem duplication mutations of the FLT3 receptor (FLT3/ITD mutations) have a poor prognosis compared to patients lacking such mutations. Incorporation of FLT3 inhibitors into existing chemotherapeutic regimens has the potential to improve clinical outcomes in this high-risk group of patients. CEP-701, an indolocarbazole-derived selective FLT3 inhibitor, potently induces apoptosis in FLT3/ITD-expressing cell lines and primary leukemic blasts. We conducted a series of in vitro cytotoxicity experiments combining CEP-701 with chemotherapy using the FLT3/ITD-expressing cell lines MV4-11 and BaF3/ITD as well as a primary blast sample from a patient with AML harboring a FLT3/ITD mutation. CEP-701 induced cytotoxicity in a synergistic fashion with cytarabine, daunorubicin, mitoxantrone, or etoposide if used simultaneously or immediately following exposure to the chemotherapeutic agent. In contrast, the combination of pretreatment with CEP-701 followed by chemotherapy was generally antagonistic, particularly with the more cell cycle-dependent agents such as cytarabine. This effect appears to be due to CEP-701 causing cell cycle arrest. We conclude that in FLT3/ITD-expressing leukemia cells, CEP-701 is synergistic with standard AML chemotherapeutic agents, but only if used simultaneously with or immediately following the chemotherapy. These results should be considered when designing trials combining chemotherapy with each of the FLT3 inhibitors currently in clinical development. (Blood. 2004; 104:1145-1150)
Tài liệu tham khảo
1 B Lowenberg JR Downing A Burnett Acute myeloid leukemia. N Engl J Med 341 1999 1051 1062 Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341: 1051-1062.
2 D Small M Levenstein Kim E STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A 91 1994 459 463 Small D, Levenstein M, Kim E, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A. 1994;91: 459-463.
3 KS Gotze M Ramirez K Tabor D Small W Matthews CI Civin Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct. Blood 91 1998 1947 1958 Gotze KS, Ramirez M, Tabor K, Small D, Matthews W, Civin CI. Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct. Blood. 1998;91: 1947-1958.
4 DG Gilliland JD Griffin The roles of FLT3 in hematopoiesis and leukemia. Blood 100 2002 1532 1542 Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100: 1532-1542.
5 M Levis Small D FLT3: ITDoes matter in leukemia. Leukemia 17 2003 1738 1752 Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia. 2003;17: 1738-1752.
6 M Nakao S Yokota Iwai T Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10 1996 1911 1918 Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10: 1911-1918.
7 H Kiyoi M Towatari Yokota S Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12 1998 1333 1337 Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12: 1333-1337.
8 Y Yamamoto H Kiyoi Nakano Y Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97 2001 2434 2439 Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97: 2434-2439.
9 FM Abu-Duhier AC Goodeve GA Wilson RS Care IR Peake JT Reilly Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 113 2001 983 988 Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol. 2001;113: 983-988.
10 M Levis D Small Novel FLT3 tyrosine kinase inhibitors. Expert Opin Investig Drugs 12 2003 1951 1962 Levis M, Small D. Novel FLT3 tyrosine kinase inhibitors. Expert Opin Investig Drugs. 2003;12: 1951-1962.
11 KF Tse E Novelli CI Civin FD Bohmer D Small Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 15 2001 1001 1010 Tse KF, Novelli E, Civin CI, Bohmer FD, Small D. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia. 2001;15: 1001-1010.
12 M Levis KF Tse BD Smith E Garrett D.A Small FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 98 2001 885 887 Levis M, Tse KF, Smith BD, Garrett E, Small D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood. 2001;98: 885-887.
13 M Levis J Allebach Tse KF A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99 2002 3885 3891 Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99: 3885-3891.
14 LM Kelly JC Yu Boulton CL CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 1 2002 421 432 Kelly LM, Yu JC, Boulton CL, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 2002;1: 421-432.
15 E Weisberg C Boulton Kelly LM Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1 2002 433 443 Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1: 433-443.
16 AM O’Farrell TJ Abrams Yuen HA SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 2003 3597 3605 O’Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101: 3597-3605.
17 KW Yee AM O’Farrell Smolich BD SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 100 2002 2941 2949 Yee KW, O’Farrell AM, Smolich BD, et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood. 2002;100: 2941-2949.
18 CL Sawyers Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 1 2002 413 415 Sawyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell. 2002;1: 413-415.
19 S Teller D Kramer Bohmer SA Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. Leukemia 16 2002 1528 1534 Teller S, Kramer D, Bohmer SA, et al. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. Leukemia. 2002;16: 1528-1534.
20 BD Smith M Levis Beran M Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103 2004 3669 3676 Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103: 3669-3676.
21 MS Tallman C Nabhan JH Feusner JM Rowe Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99 2002 759 767 Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99: 759-767.
22 BJ Druker CL Sawyers Kantarjian H Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 2001 1038 1042 Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344: 1038-1042.
23 ME Gorre M Mohammed Ellwood K Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 2001 876 880 Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293: 876-880.
24 R Palacios M Steinmetz Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41 1985 727 734 Palacios R, Steinmetz M. Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell. 1985;41: 727-734.
25 B Lange M Valtieri Santoli D Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 70 1987 192 199 Lange B, Valtieri M, Santoli D, et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood. 1987;70: 192-199.
26 TC Chou P Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 1984 27 55 Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22: 27-55.
27 WT Dalton Jr MJ Ahearn KB McCredie EJ Freireich SA Stass JM. Trujillo HL-60 cell line was derived from a patient with FAB-M2 and not FABM3. Blood 71 1988 242 247 Dalton WT Jr, Ahearn MJ, McCredie KB, Freireich EJ, Stass SA, Trujillo JM. HL-60 cell line was derived from a patient with FAB-M2 and not FABM3. Blood. 1988;71: 242-247.
28 S Eksborg H Ehrsson B Ekqvist Protein binding of anthraquinone glycosides, with special reference to adriamycin. Cancer Chemother Pharmacol 10 1982 7 10 Eksborg S, Ehrsson H, Ekqvist B. Protein binding of anthraquinone glycosides, with special reference to adriamycin. Cancer Chemother Pharmacol. 1982;10: 7-10.
29 O Chassany S Urien P Claudepierre G Bastian JP Tillement Comparative serum protein binding of anthracycline derivatives. Cancer Chemother Pharmacol 38 1996 571 573 Chassany O, Urien S, Claudepierre P, Bastian G, Tillement JP. Comparative serum protein binding of anthracycline derivatives. Cancer Chemother Pharmacol. 1996;38: 571-573.
30 GJ Finlay BC Baguley Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemother Pharmacol 45 2000 417 422 Finlay GJ, Baguley BC. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemother Pharmacol. 2000;45: 417-422.
31 R Stone V Klimeck DeAngelo DJ PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): a phase II clinical trial [abstract]. Blood 100 2002 86a Stone R, Klimeck V, DeAngelo DJ, et al. PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): a phase II clinical trial [abstract]. Blood. 2002;100: 86a.